Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Cell Physiol Biochem ; 45(1): 148-162, 2018.
Article in English | MEDLINE | ID: mdl-29334683

ABSTRACT

BACKGROUND/AIMS: Human mutL homolog 1 (MLH1) promoter methylation was reported in gastric cancer (GC). This study determined the clinicopathological, prognostic, and diagnostic effects of MLH1 promoter methylation in GC. METHODS: The combined odds ratio (OR) or hazard ratio (HR) and their corresponding 95% confidence intervals (95% CI) were calculated. The pooled sensitivity, specificity, and area under the curve (AUC) were analyzed. RESULTS: A total of 4654 GC patients and 3669 non-malignant controls were identified in this systematic analysis. MLH1 promoter methylation was significantly higher in GC samples than in gastric adenomas, chronic gastritis, adjacent tissues, normal gastric mucosa, and normal healthy blood samples, but it exhibited a similar frequency in GC vs. intestinal metaplasia and dysplasia samples. MLH1 promoter methylation correlated with age and microsatellite instability (MSI), but it was not associated with gender, H. pylori infection, smoking, drinking behaviors, pathological histology, tumor differentiation, clinical stage, lymph node status, distant metastasis, or overall survival of GC. MLH1 promoter methylation exhibited a poor sensitivity value (< 0.5) in patients with GC compared with adjacent tissues, gastric adenomas, chronic gastritis, normal gastric mucosa, and normal healthy blood samples. The pooled sensitivity, specificity, and AUC of MLH1 promoter methylation in GC with MSI vs. GC with microsatellite stability (MSS) samples were 0.64, 0.96, and 0.90, respectively. CONCLUSIONS: Our results suggest that the detection of MLH1 promoter methylation may be a potential prognostic biomarker for GC patients with MSI.


Subject(s)
Biomarkers, Tumor/metabolism , MutL Protein Homolog 1/metabolism , Stomach Neoplasms/pathology , Age Factors , Area Under Curve , Biomarkers, Tumor/genetics , DNA Methylation , Disease-Free Survival , Epigenesis, Genetic , Gastric Mucosa/metabolism , Humans , Microsatellite Instability , MutL Protein Homolog 1/antagonists & inhibitors , MutL Protein Homolog 1/genetics , Odds Ratio , Promoter Regions, Genetic , Proportional Hazards Models , ROC Curve , Stomach Neoplasms/genetics , Stomach Neoplasms/mortality , Survival Rate
2.
Mol Carcinog ; 56(7): 1816-1824, 2017 07.
Article in English | MEDLINE | ID: mdl-28224663

ABSTRACT

Germline mutations of MLH1 are responsible for tumor generation in nearly 50% of patients with Lynch Syndrome, and around 15% of sporadic colorectal cancers show MLH1-deficiency due to promotor hypermethylation. Although these tumors are of lower aggressiveness the benefit for these patients from standard chemotherapy is still under discussion. Recently, it was shown that the sensitivity to the DNA-PKcs inhibitor KU60648 is linked to loss of the MMR protein MSH3. However, loss of MSH3 is rather secondary, as a consequence of MMR-deficiency, and frequently detectable in MLH1-deficient tumors. Therefore, we examined the expression of MLH1, MSH2, MSH6, and MSH3 in different MMR-deficient and proficient cell lines and determined their sensitivity to KU60648 by analyzing cell viability and survival. MLH1-dependent ability of double strand break (DSB) repair was monitored after irradiation via γH2AX detection. A panel of 12 colon cancer cell lines, two pairs of cells, where MLH1 knock down was compared to controls with the same genetic background, and one MLH1-deficient cell line where MLH1 was overexpressed, were included. In summary, we found that MLH1 and/or MSH3-deficient cells exhibited a significantly higher sensitivity to KU60648 than MMR-proficient cells and that overexpression of MLH1 in MLH1-deficient cells resulted in a decrease of cell sensitivity. KU60648 efficiency seems to be associated with reduced DSB repair capacity. Since the molecular testing of colon tumors for MLH1 expression is a clinical standard we believe that MLH1 is a much better marker and a greater number of patients would benefit from KU60648 treatment.


Subject(s)
Colonic Neoplasms/drug therapy , DNA-Activated Protein Kinase/antagonists & inhibitors , Drug Resistance, Neoplasm/drug effects , MutL Protein Homolog 1/antagonists & inhibitors , Nuclear Proteins/antagonists & inhibitors , Protein Kinase Inhibitors/pharmacology , Apoptosis/drug effects , Cell Proliferation/drug effects , Colonic Neoplasms/metabolism , Colonic Neoplasms/pathology , DNA Mismatch Repair/drug effects , Humans , MutL Protein Homolog 1/genetics , MutL Protein Homolog 1/metabolism , RNA, Small Interfering/genetics , Tumor Cells, Cultured
3.
Nucleic Acids Res ; 45(3): 1219-1232, 2017 02 17.
Article in English | MEDLINE | ID: mdl-28180301

ABSTRACT

Aberrant formation of interstitial telomeric sequences (ITSs) promotes genome instabilities. However, it is unclear how aberrant ITS formation is suppressed in human cells. Here, we report that MLH1, a key protein involved in mismatch repair (MMR), suppresses telomeric sequence insertion (TSI) at intra-chromosomal regions. The frequency of TSI can be elevated by double-strand break (DSB) inducer and abolished by ATM/ATR inhibition. Suppression of TSI requires MLH1 recruitment to DSBs, indicating that MLH1's role in DSB response/repair is important for suppressing TSI. Moreover, TSI requires telomerase activity but is independent of the functional status of p53 and Rb. Lastly, we show that TSI is associated with chromosome instabilities including chromosome loss, micronuclei formation and chromosome breakage that are further elevated by replication stress. Our studies uncover a novel link between MLH1, telomerase, telomere and genome stability.


Subject(s)
MutL Protein Homolog 1/genetics , MutL Protein Homolog 1/metabolism , Telomerase/genetics , Telomerase/metabolism , Telomere/genetics , Telomere/metabolism , Ataxia Telangiectasia Mutated Proteins/antagonists & inhibitors , Ataxia Telangiectasia Mutated Proteins/metabolism , Cell Line , Chromosomal Instability , DNA Breaks, Double-Stranded , DNA Mismatch Repair , DNA Transposable Elements , Gene Knockdown Techniques , HCT116 Cells , HeLa Cells , Humans , MutL Protein Homolog 1/antagonists & inhibitors , RNA, Small Interfering/genetics , Retinoblastoma Protein/metabolism , Tumor Suppressor Protein p53/metabolism
4.
Cell Prolif ; 50(1)2017 Feb.
Article in English | MEDLINE | ID: mdl-27868267

ABSTRACT

BACKGROUND AND AIMS: Human mutL homologl (MLH1) works coordinately in sequential steps to initiate repair of DNA mismatches, and aberrant MLH1 expression is related to spermatogenetic malfunction. In the present study, MLH1 expression in patients with azoospermia was investigated, and moderating effects of miR-188-3p on MLH1 expression and spermatogenesis were identified. METHODS: Testicular tissues from 16 patients with obstructive azoospermia (OA) and non-obstructive azoospermia (NOA), and tissues of eight healthy patients were collected. Real-time PCR, Western blotting and immunohistochemical staining were used to detect MLH1 expression. Chromatin immunoprecipitation assay and luciferase reporter assay were performed to evaluate histone acetylation level of miR-188-3p and relationships between miR-188-3p and MLH1. RESULTS: Testicular MLH1 expression at mRNA and protein levels was significantly increased, while miR-188-3p expression was lower in patients with OA and NOA than that in controls. Reduced histone acetylation level of miR-188-3p promoter was observed in patients with azoospermia. Overexpression/inhibition of HDAC1, but not HDAC2, contributed to the significant reduction/increase of miR-188-3p expression. miR-188-3p targeted 3' UTR of MLH1 and regulated MLH1 expression. miR-188-3p inhibitor led to elevation of apoptotic level of spermatogenic cells in mice, while this effect was reversed by si-MLH1. CONCLUSION: Down-regulation of miR-188-3p by reducing histone acetylation up-regulated MLH1 expression and contributed to promotion of apoptosis in spermatogenic cells, in patients with azoospermia.


Subject(s)
Apoptosis/genetics , Azoospermia/pathology , Down-Regulation , MicroRNAs/metabolism , MutL Protein Homolog 1/genetics , MutL Protein Homolog 1/metabolism , Spermatocytes/cytology , Acetylation , Animals , Antagomirs/metabolism , Azoospermia/genetics , Azoospermia/metabolism , Base Sequence , Cell Line , Histone Deacetylase 1/genetics , Histone Deacetylase 1/metabolism , Histone Deacetylase 2/genetics , Histone Deacetylase 2/metabolism , Histones/metabolism , Humans , Male , Mice , MicroRNAs/antagonists & inhibitors , MicroRNAs/genetics , MutL Protein Homolog 1/antagonists & inhibitors , Promoter Regions, Genetic/genetics , RNA Interference , Sequence Alignment , Spermatogenesis
SELECTION OF CITATIONS
SEARCH DETAIL
...